tbuckley/cabot-search huggingface dataset:
Abstract P169: Association of Kidney Function and Risk of Hospitalized Bone Fracture
Authors: Natalie R Daya, Annie Voskertchian, Andrea L Schneider, Shoshana Ballew, Mara McAdams DeMarco, Josef Coresh, Lawrence Appel, Elizabeth Selvin, Morgan E Grams
Journal: Circulation (2015)

Introduction: Persons with end-stage renal disease are at high risk of fracture. Less is known about fracture risk in milder chronic kidney disease (CKD), particularly in persons with albuminuria but preserved estimated glomerular filtration rate (eGFR), and whether CKD-associated fracture risk varies by sex.

Methods: Participants from the ARIC study were followed from 1996-2011. Kidney function was assessed at baseline by eGFR and urine albumin-to-creatinine ratio (ACR). Fracture-related diagnostic codes were identified through active surveillance of hospitalizations. Cox proportional hazards models were adjusted for demographic factors and other established risk factors for osteoporosis and fracture.

Results: Among 11,000 eligible participants (mean age 63.3 years, 55.9% female, 21.9% black), there were 722 fracture-related hospitalizations during a median follow-up of 13 years. Below eGFR 60 ml/min/1.73 m2, lower eGFR was associated with higher fracture risk (adjusted hazard ratio (aHR) per 10 ml/min/1.73 m2 lower eGFR: 1.49; 95% CI, 1.27, 1.75), independent of ACR (Figure). Above eGFR 60 ml/min/1.73 m2, there was no association between eGFR and fracture risk. There was a strong relationship between ACR and fracture, independent of eGFR (aHR per log-increase, 1.14; 95% CI, 1.08-1.20). More severe stages of both GFR and albuminuria conferred higher fracture risk. Even among those with eGFR ≥60 ml/min/1.73 m2, persons with ACR >300 mg/g or ACR 30-300 mg/g had higher fracture risk than those with ACR <30mg/g (adjusted incidence rate (aIR): 9.21; 95% CI, 5.00-17.12, aIR: 7.43; 95% CI, 5.59 -9.89, aIR: 5.17; 95% CI, 4.76-5.60, respectively). There was no difference in associations by sex (eGFR: p for interaction= 0.9; albuminuria: p for interaction= 0.6).

Conclusions: Low eGFR and albuminuria were independent risk factors for fracture-related hospitalization in both men and women in this community-based population. Persons with kidney disease might benefit from fracture prevention strategies.

   ![][1]  [1]: /embed/graphic-1.gif
Autoimmune Renal Disease Is Exacerbated by S1P-Receptor-1-Dependent Intestinal Th17 Cell Migration to the Kidney
Authors: Christian F. Krebs, Hans-Joachim Paust, Sonja Krohn, Tobias Koyro, Silke R. Brix, Jan-Hendrik Riedel, Patricia Bartsch, Thorsten Wiech, Catherine Meyer-Schwesinger, Jiabin Huang, Nicole Fischer, Philipp Busch, Hans-Willi Mittrücker, Ulrich Steinhoff, Brigitta Stockinger, Laura Garcia Perez, Ulrich O. Wenzel, Matthias Janneck, Oliver M. Steinmetz, Nicola Gagliani, Rolf A.K. Stahl, Samuel Huber, Jan-Eric Turner, Ulf Panzer
Journal: Immunity (2016)

Th17 cells are most abundant in the gut, where their presence depends on the intestinal microbiota. Here, we examined whether intestinal Th17 cells contribute to extra-intestinal Th17 responses in autoimmune kidney disease. We found high frequencies of Th17 cells in the kidneys of patients with antineutrophil cytoplasmatic antibody (ANCA)-associated glomerulonephritis. We utilized photoconversion of intestinal cells in Kaede mice to track intestinal T cell mobilization upon glomerulonephritis induction, and we found that Th17 cells egress from the gut in a S1P-receptor-1-dependent fashion and subsequently migrate to the kidney via the CCL20/CCR6 axis. Depletion of intestinal Th17 cells in germ-free and antibiotic-treated mice ameliorated renal disease, whereas expansion of these cells upon Citrobacter rodentium infection exacerbated pathology. Thus, in some autoimmune settings, intestinal Th17 cells migrate into target organs, where they contribute to pathology. Targeting the intestinal Th17 cell "reservoir" may present a therapeutic strategy for these autoimmune disorders.
Improved Leukemia-Free Survival after Post-Consolidation Treatment with Histamine Dihydrochloride and Interleukin-2 in AML: A Randomized Phase III Trial.
Authors: Mats Brune, Sylvie Castaigne, John Catalano, Kurt Gehlsen, Wolf-Karsten Hofmann, Anthony Ho, Donna Hogge, Bo Nilsson, Reuven Or, Jacob Rowe, Bengt Simonsson, Ruth Spearing, Edward Stadtmauer, Jeff Szer, Elisabeth Wallhult, Kristoffer Hellstrand
Journal: Blood (2004)
Invasive Pulmonary Aspergillosis in AML and ALL Patients Hospitalized into an Intensive Care Unit Divided into 2 Areas with a Different Specific Air Environment: Evaluation of Posaconazole Prophylaxis and Comparison Between the Two Specific Air Environment Areas
Authors: Marie Y. Detrait, Stephane Morisset, Jean-Pierre Delville, Arnaud Lixon, Sabine Meurisse, Xavier Holemans, Nathalie De Visscher, Philippe Mineur, Delphine Pranger, Margareta Nedelcu, Julien Depaus, Martin Di Biase, Celine Van Wetter, Francoise Anckaert, Anne Kornreich, Jean-Luc Canon
Journal: Blood (2014)
FRI0421 What Is The Location of Enthesitis in Ankylosing Spondylitis and Psoriatic Arthritis Patients and How Do They Respond To Anti-TNF Treatment?: Table 1
Authors: J. Kelsall, D. Choquette, P. Rahman, R. Arendse, M. Teo, I. Fortin, J.A. Avina-Zubieta, E. Rampakakis, E. Psaradellis, K. Maslova, B. Osborne, C. Tkaczyk, F. Nantel, A.J. Lehman
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Enthesitis is characterized by inflammation at the insertion of ligaments, tendons, joint capsule, or fascia to bone, and represents a well-known characteristic feature of ankylosing spondylitis (AS) and related spondyloarthropathies. <h3>Objectives</h3> To identify the location of enthesitis in ankylosing spondylitis (AS) and psoriatic arthritis (PsA) patients and to determine their response to anti-TNF treatment. <h3>Methods</h3> BioTRAC is an ongoing, prospective registry of patients initiating treatment for rheumatoid arthritis, AS, or psoriatic arthritis (PsA) with infliximab (IFX) or golimumab (GLM). Eligible people for this analysis included AS and PsA patients treated with IFX who were enrolled since 2005 or with GLM enrolled since 2010 who had available information on enthesitis. The paired sampled t-test was used to compare the enthesitis count at baseline and 12 months. <h3>Results</h3> A total of 260 AS patients and 261 PsA patients were enrolled with a mean (SD) age at baseline of 46.1 (13.0) vs. 50.0 (12.0) years, respectively, and disease duration of 6.4 (9.8) vs. 5.2 (6.8) years. Among patients with AS, 28.1%, 21.7%, 22.4% had enthesitis at baseline, 6 months and 12 months, respectively. For PsA these numbers were 32.2%, 19.7%, and 22.6%, respectively. The presence of enthesitis by anatomical site and visit are described in Table 1 with higher proportions observed for the greater trochanter (GT) in AS patients and the lateral epicondyle humerus (LEH) in PsA patients. Presence of enthesitis in all anatomical sites was significantly associated with higher HAQ among AS and PsA patients. The mean (SD) enthesitis count at baseline and 12 months was 4.4 (3.4) vs. 2.6 (2.3) (P=0.061) among AS patients and 5.0 (3.8) vs. 3.8 (3.0) (P=0.006) in PsA patients, respectively. <h3>Conclusions</h3> A considerable proportion of PsA and AS patients had enthesitis at anti-TNF initiation in this Canadian real-world cohort. Overall, presence of enthesitis was associated with significantly higher functional disability. Treatment with IFX or GLM for 12 months was associated with significant reduction in the mean enthesitis count. <h3>Disclosure of Interest</h3> J. Kelsall: None declared, D. Choquette: None declared, P. Rahman: None declared, R. Arendse: None declared, M. Teo: None declared, I. Fortin: None declared, J. A. Avina-Zubieta: None declared, E. Rampakakis: None declared, E. Psaradellis: None declared, K. Maslova Employee of: Janssen Inc., B. Osborne Employee of: Janssen Inc., C. Tkaczyk Employee of: Janssen Inc., F. Nantel Employee of: Janssen Inc., A. Lehman Employee of: Janssen Inc.
THU0426 Achilles Enthesitis Defined by Ultrasound Is Not Associated To Clinical Enthesitis in Patients with Psoriatic Arthritis
Authors: B. Michelsen, A.P. Diamantopoulos, D.M. Soldal, H.B. Hammer, A. Kavanaugh, G. Haugeberg
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Clinical examination may overestimate Achilles enthesitis. Ultrasonography (US) is a valuable tool for assessment of musculoskeletal inflammation including subclinical enthesitis. <h3>Objectives</h3> The aim of our study was to compare clinical and US evaluation of Achilles enthesitis in patients with psoriatic arthritis (PsA). <h3>Methods</h3> Patients with PsA were included consecutively in a clinical setting during 1.5 years. The Achilles insertion was examined by clinical assessment of tenderness by a trained nurse, and an experienced ultrasonographer performed US evaluation of 1) inflammatory activity defined as power Doppler (PD) signal, tendon thickening, hypoechogenicity and bursal swelling as well as 2) structural damage defined as erosions at tendon insertion, calcifications and enthesophytes. US sum scores of inflammatory activity and structural damage were assessed. Demographic variables and US scores were assessed by descriptive statistics. Proportions were analysed by Chi-Square test. Correlations were assessed by Spearman9s rank correlation test (non-parametric distribution of the data). <h3>Results</h3> A total of 141 PsA patients were included. They all fulfilled the CASPAR criteria. Mean (SD) age was 52.4 (10.2) years, disease duration 9.5 (6.6) years, BMI 28.3 (4.3) kg/m<sup>2</sup>, 50.4% were females, 10.6% used steroids, 57.4% conventional synthetic disease modifying drugs (csDMARDs), 32.6% tumor necrosis factor inhibitors (TNFi) and 20.6% both TNFi and csDMARDs. Of 282 Achilles tendons, 88 (33.2%) were tender on palpation. By US, 6 (17%) had hypoechogenicity, 37 (13.1%) thickening, 2 (0.8%) PD activity, 14 (5%) bursal swelling, 112 (39.7%) calcifications, 77 (27.3%) enthesophytes and 4 (1.4%) erosions at tendon insertion. Inflammatory activity was found in 55 (19.5%) of the examined Achilles tendons and 148 (52.5%) had structural damage on US sum scores. No significant correlation was found between US sum scores and tenderness on palpation. 36 (18.6%) of the Achilles tendons showed subclinical inflammation on US. No significant difference of percentages of patients with Achilles inflammatory activity or structural damage was found when comparing patients currently treated or not with TNFi, csDMARDs and steroids. <h3>Conclusions</h3> We report lack of association between palpation tenderness and US signs of Achilles enthesitis in PsA. US showed structural damage in 52.5% and subclinical inflammation in 18.6% of the examined Achilles tendons. <h3>Disclosure of Interest</h3> B. Michelsen: None declared, A. Diamantopoulos Consultant for: Pfizer, Novartis, Speakers bureau: Abbvie, UCB, Pfizer, D. Soldal: None declared, H. Hammer Speakers bureau: AbbVie, Pfizer, Roche, UCB and BMS, A. Kavanaugh: None declared, G. Haugeberg: None declared
Effects of Irradiation on the Functional Characteristics of Human Bone Marrow Mesenchymal Stromal/Stem Cells
Authors: Masaki Iwasa, Yasuo Miura, Aya Fujishiro, Akihiro Tamura, Atsushi Sato, Asumi Yokota, Yoko Nakagawa, Satoshi Yoshioka, Hideyo Hirai, Akira Andoh, Tatsuo Ichinohe, Taira Maekawa
Journal: Blood (2014)
SP0002 Systemic Sclerosis
Authors: J. Varga
Journal: Annals of the Rheumatic Diseases (2016)

Scleroderma remains a challenging disease with no effective therapy. Obstacles to development of effective therapies include the complex, multifactorial pathogenesis, lack of clear etiologic agent, uncertain role of genetic risks; patient-to-patient variability in clinical manifestations and disease outcomes; variable rates of disease progression in different organs in the same individual; lack of validated biomarkers, and lack of consensus regarding optimal clinical trial design. Each of these obstacles is being addressed by current research, and significant progress is being achieved. A large number of plausible drug targets have been identified and are being validated in preclinical models. Innovative clinical trial designs and increasingly more robust outcome measures allow more effective drug testing. Molecular omics approaches further facilitate patient stratification, and matching drugs to patients in an increasingly personalized precision approach to management. <h3>Disclosure of Interest</h3> None declared
Survival Outcomes Of Very Young (&lt;40 years) Myeloma Patients
Authors: Utkarsh Painuly, Shivlal Pandey, Shaji K Kumar, Robert Kyle, Martha Q Lacy, Morie A Gertz, Vincent Rajkumar, Suzanne R Hayman, Francis Buadi, David Dingli, Stephen J. Russell, John A Lust, Arleigh McCurdy, Angela Dispenzieri, Prashant Kapoor
Journal: Blood (2013)
PWE-069 Sampling Oesophageal Microbial Communities in Barrett’s Oesophagus Using Minimally Invasive and Endoscopic Methods
Authors: DR Fels Elliott, AW Walker, M O’Donovan, J Parkhill, RC Fitzgerald, G Contino
Journal: Gut (2016)

<h3>Introduction</h3> Minimally invasive methods for sampling the oesophageal microbiota may be clinically useful for detection and risk stratification of patients with Barrett’s oesophagus. The Cytosponge is a non-endoscopic device that samples epithelial cells and bacteria along the length of the oesophagus. This study aimed to determine the utility of the Cytosponge for sampling the oesophageal microbiota, and to assess whether the device could detect altered microbiota in Barrett’s oesophagus. <h3>Methods</h3> 251 samples from 67 patients and relevant negative controls underwent 16 S rRNA gene sequencing (in duplicate) on the Illumina MiSeq platform. A subset of Cytosponge samples (N = 31) was compared with matched fresh frozen endoscopic biopsies (N = 31), endoscopic brushings (N = 31) and throat swabs (N = 13). The microbial DNA yield for the different oesophageal sample types was analysed using quantitative PCR for overall bacterial abundance. 16 S rRNA gene data was further interrogated from patients representing the Barrett’s progression sequence, including normal squamous oesophagus (N = 20), Barrett’s oesophagus (N = 24), and high grade dysplasia (N = 23). <h3>Results</h3> 16 S rRNA gene data showed the majority of genera overlapped between Cytosponge samples and endoscopic brushes and biopsies (84%, cut-off &gt;0.0001% abundance; 100%, cut-off &gt;0.1% abundance), but the Cytosponge samples were enriched for genera known to be prevalent in the stomach and oral cavity such as <i>Campylobacter </i>and <i>Fusobacterium</i>, respectively (q &lt; 0.05, Metastats). The Cytosponge yielded higher quantity of microbial DNA in comparison to endoscopic brushes or endoscopic biopsies (P &lt; 0.001). Furthermore, the Cytosponge detected decreased diversity in patients with high grade dysplasia, in comparison to normal squamous controls (P &lt; 0.05), suggesting that some taxa may have a competitive advantage over others in this disease state. There was also a trend towards decreased diversity in non-dysplastic Barrett’s oesophagus compared to normal squamous controls, which reached significance for the Shannon index and inverse Simpson index (P &lt; 0.05). There was no difference in microbial diversity between non-dysplastic Barrett’s oesophagus and high grade dysplasia. <h3>Conclusion</h3> The Cytosponge was capable of sampling the microbiota in the oesophagus and proximal stomach, and detected decreased diversity in patients with high grade dysplasia compared to normal squamous oesophagus. <h3>Disclosure of Interest</h3> D. R. Fels Elliott: None Declared, A. Walker: None Declared, M. O’Donovan: None Declared, J. Parkhill: None Declared, R. Fitzgerald Grant/research support from: RCF developed the Cytosponge™ technology with MRC-Technology, which provided devices for research. The Cytosponge™ has recently been licensed to Covidien, and RCF has no direct financial relationship with Covidien.
FRI0292 Risk Factors for Recurrence of Polymyositis/dermatomyositis Associated Interstitial Lung Disease
Authors: M. Nakazawa, Y. Kaneko, T. Takeuchi
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Polymyositis (PM)/dermatomyositis (DM) are characterized by a systemic inflammation of a proximal skeletal muscles and/or a skin. Interstitial lung disease (ILD) is a common but life-threatening complication with PM/DM and often recurs despite intensive induction therapy. However, risk factors for the ILD flare are not determined. <h3>Objectives</h3> To identify risk factors of the recurrence of PM/DM-ILD. <h3>Methods</h3> Consecutive patients with PM/DM-ILD treated in our institution from 2002 to 2015 were enrolled in the study. The patients were divided into two groups according to the presence or absence of recurrence of ILD after the improvement by induction therapy; the recurrence group and the non-recurrence group. The patients were observed until the recurrence or the last visit to our clinic. The patients9 characteristics and treatment between the two groups were compared. <h3>Results</h3> A total of forty four patients with PM/DM-ILD underwent induction therapy. After excluding 1 deceased patient (induction failure) and 1 lost to follow-up, forty five PM/DM-ILD cases who had been treated with predonisolone (PSL) and/or immunosuppressive agents as induction therapy were included in the analysis. Recurrence occurred in 17 cases (37.8%). The mean duration from the time of induction therapy to the recurrence was 124 (42.5–241.0) weeks. The following period was 338.5 (166.3–777.5) weeks in the non-recurrence group. At the time of induction therapy, no difference was found between the recurrence group and the non-recurrence group in the mean age (47.6±14.3 vs 47.8±11.9 years, P=0.95), the male ratio (23.5% vs 30.8%, P=0.54), and the proportion of DM (64.7% vs 78.6%, P=0.31), respectively. The levels of C-reactive protein, lactate dehydrogenase and KL-6 were also not different. The percentage of vital capacity (%VC) in the recurrence group was lower than that of the non- recurrence group (59.6% vs 78.3%, P=0.004). The induction therapy regimen was not different between the 2 groups; glucocorticoid pulse, 17.6% vs 21.4% (P=0.84), the initial PSL dose, 0.87 mg/kg vs 0.89 mg/kg (P=0.17), the concomitant use of immunosuppressive agents including cyclophosphamide and/or calcineurine inhibitor with PSL, 47.1% vs 50.0% (P=0.85), in the recurrence and the non-recurrence group, respectively. The PSL dose was 8.3 mg at the recurrence in the recurrence group, and 7.9 mg at the last observation in the non-recurrence group (P=0.40). Immunosuppressive agent was more frequently used as maintenance therapy in the non-recurrence group than the recurrence group (89.3% vs 64.7%, P=0.047). <h3>Conclusions</h3> PM/DM-ILD patients with low %VC at the induction therapy are inclined to recur. The concomitant use of immunosuppressive agent as maintenance after induction is important to prevent the recurrence of PM/DM-ILD. The study can improve the management of the PM/DM-ILD. <h3>Disclosure of Interest</h3> None declared
SLAMF1/CD150 Activates Autophagy in Chronic Lymphocytic Leukemia Cells, Modulating Chemotaxis and Responses to Therapy
Authors: Cinzia Bologna, Roberta Buonincontri, Sara Serra, Tiziana Vaisitti, Valentina Audrito, Davide Brusa, Andrea Pagnani, Marta Coscia, Giovanni D'Arena, Erica B. Bhavsar, Richard R. Furman, Davide Rossi, Gianluca Gaidano, Cox Terhorst, Silvia Deaglio
Journal: Blood (2015)
PTH-023 Histology, Cytology or Both for Sampling of Solid Pancreatic Masses? Prospective Evaluation of A New 22G Biopsy Needle: Abstract PTH-023 Table 1
Authors: I Penman, N McAvoy, P Fineron, S Siddhi, U Basavaraju, G Murray
Journal: Gut (2016)

<h3>Introduction</h3> For solid pancreatic masses (SPM), EUS-fine needle aspiration cytology (FNA-C) has a variable diagnostic yield and sensitivity for diagnosis of malignancy, given the limited material, presence of inflammation and inherent difficulties in cytologic interpretation. Histology of formalin-fixed biopsies is simpler, cheaper and may allow extra marker studies more often. This study evaluated the ability of a new EUS biopsy needle (1) to obtain histological biopsies (FNB) with a limited number of passes; (2) to compare specimen adequacy and diagnostic sensitivity with FNA-C; (3) compare specimen quality between FNA-C and FNB. <h3>Methods</h3> Over 5 months, consecutive patients with SPM underwent EUS biopsy sampling using a standardised protocol. Patients in whom lesions were predominantly cystic, taking anticoagulants or in whom access with a 22 g needle was deemed impossible were excluded. Using a 22 g ‘Sharkcore’ needle (Medtronic, Dublin, Ireland), 4 passes were made, using slow stylet withdrawal and material expelled into Cytolyt cytology fixative (2 passes) or into formalin for histology processing. Sampling sequence was randomised (passes 1&amp;3 into cytology with passes 2&amp;4 into formalin, or vice versa). Pathological assessment was performed by one of 2 specialist GI pathologists using a structured proforma, to rate specimen adequacy, sample quality, diagnosis and subjective superiority. <h3>Results</h3> 43 patients were included (23 M, 20 F, mean age 66 years, range 46–83 y). One patient was excluded from analysis due to incomplete follow-up. Final diagnoses were pancreatic malignancy (35, 83.3%) and benign pancreaticobiliary disorders (7, 16.7%). Results (n = 42) are shown in Table 1: In 2 cases FNA-cytology was negative for malignancy but FNB histology was positive; in contrast there were no cases where cytology was positive but histology was negative. Subjectively, FNB histology samples were scored as superior in 28 cases (66.7%), compared to FNA-C samples (4, 9.5%). In the remainder, samples were judged to be of equivalent quality (10, 23.8%). <h3>Conclusion</h3> The 22 g Sharkcore needle provides histological-quality samples in almost all cases of pancreatic or peripancreatic masses, with only 2 passes. Samples are more often superior to those obtained by cytology. This offers the prospect of shorter procedure times, easier sample processing and more reliable diagnosis. <h3>Disclosure of Interest</h3> None Declared
Bone Marrow Hypocellularity, Decreased Platelet Counts and Colony Forming Units Serve as Prognostics Parameters for Early Complications after Autologous Peripheral Blood Stem Cell Transplantation.
Authors: Antonia M.S. Mueller, Gabriele Ihorst, Denz Ulrich, Doeing Carsten, Wider Dagmar, Engelhardt Monika
Journal: Blood (2005)
Shorter Time to Achieve a Major Molecular Response (MMR) Is Predictive of a Faster Complete Molecular Response in CML: A Study of Characteristics and Outcomes of a Cohort of CML Patients in MMR
Authors: Mauricette Michallet, Mohamad Sobh, Stephane Morisset, Madeleine Etienne, Elodie Gadolet, Helene Labussiere, Sandrine Hayette, Franck E. Nicolini
Journal: Blood (2011)
Molecular Analysis of Myelodysplastic Syndrome with Isolated Del(5q) Reveals a Broad Spectrum of Clinically Relevant Mutations: A Study on 119 Patients and 26 Genes
Authors: Manja Meggendorfer, Tamara Alpermann, Claudia Haferlach, Susanne Schnittger, Wolfgang Kern, Torsten Haferlach
Journal: Blood (2014)